DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1d ago
1GXI logo

Gerresheimer AGBIT:1GXI Stock Report

Market Cap €974.7m
Updated 1d ago
Share Price
n/a
1Y-33.2%
7D0.6%
1D-1.6%
Portfolio Value
​
View

Gerresheimer AG

BIT:1GXI Stock Report

Market Cap: €974.7m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Gerresheimer (1GXI) Stock Overview

Provides drug containment solutions in Germany and internationally. More details

1GXI fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Rewards

Trading at 37.5% below our estimate of its fair value

Earnings are forecast to grow 98.74% per year

Trading at good value compared to peers and industry

Risk Analysis

Interest payments are not well covered by earnings

Volatile share price over the past 3 months compared to the Italian market


1GXI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,757 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
439,757 investors already sharing narratives
€
Current Price
€28.5086.7% undervalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-320m3b2016201920222025202620282031Revenue €2.8bEarnings €366.7m
Advanced
View all narratives

Gerresheimer AG Competitors

Fine Foods & Pharmaceuticals N.T.M

Symbol: BIT:FF
Market cap: €161.4m

Beijing Sun-Novo Pharmaceutical Research

Symbol: SHSE:688621
Market cap: CN¥7.5b

Akums Drugs and Pharmaceuticals

Symbol: NSEI:AKUMS
Market cap: ₹118.9b

ChemoMetec

Symbol: CPSE:CHEMM
Market cap: DKK 8.6b

Price History & Performance

Summary of share price highs, lows and changes for Gerresheimer
Historical stock prices
Current Share Price€28.50
52 Week High€32.22
52 Week Low€15.80
Beta0.48
1 Month Change5.79%
3 Month Change15.11%
1 Year Change-33.16%
3 Year Changen/a
5 Year Changen/a
Change since IPO-56.29%

Recent News & Updates

Recent updates

Shareholder Returns

1GXIIT Life SciencesIT Market
7D0.6%-3.4%0.6%
1Y-33.2%3.9%19.1%

Return vs Industry: 1GXI underperformed the Italian Life Sciences industry which returned 3.4% over the past year.

Return vs Market: 1GXI underperformed the Italian Market which returned 18.1% over the past year.

Price Volatility

Is 1GXI's price volatile compared to industry and market?
1GXI volatility
1GXI Average Weekly Movement6.6%
Life Sciences Industry Average Movement5.7%
Market Average Movement4.1%
10% most volatile stocks in IT Market7.4%
10% least volatile stocks in IT Market2.6%

Stable Share Price: 1GXI's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: 1GXI's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.

About the Company

FoundedEmployeesCEOWebsite
186413,528Uwe Röehrhoffwww.gerresheimer.com

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors.

Gerresheimer AG Fundamentals Summary

How do Gerresheimer's earnings and revenue compare to its market cap?
1GXI fundamental statistics
Market cap€974.72m
Earnings (TTM)-€320.32m
Revenue (TTM)€2.32b
0.4x
P/S Ratio
-3.0x
P/E Ratio

Is 1GXI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GXI income statement (TTM)
Revenue€2.32b
Cost of Revenue€1.77b
Gross Profit€548.29m
Other Expenses€868.61m
Earnings-€320.32m

Last Reported Earnings

Nov 30, 2025

Next Earnings Date

Oct 15, 2026

Earnings per share (EPS)-9.27
Gross Margin23.62%
Net Profit Margin-13.80%
Debt/Equity Ratio198.6%

How did 1GXI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 18:38
End of Day Share Price 2026/09/11 00:00
Earnings2025/11/30
Annual Earnings2025/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gerresheimer AG is covered by 30 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav JainBarclays
Jonathon UnwinBarclays
Pallav MittalBarclays

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide